NEW YORK – Drug discovery startup Integrated Biosciences said Thursday that it has raised $17.2 million in seed financing.
The round was led by Sutter Hill Ventures, with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund, Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan.
Integrated Biosciences plans to use the money to accelerate development of its drug pipeline, further develop its technology platform, and ramp up its commercialization efforts.
Founded in September 2022, Redwood City, California-based Integrated Biosciences deploys ultrahigh throughput gene expression analysis and epigenetic sequencing to help discover small molecule drugs for aging-related diseases. The firm has licensed technology developed by Cofounder Max Wilson at the University of California, Santa Barbara that uses optogenetic modulation of molecular stress response.
"Our synthetic biology platform gives us access to the purest stress responses, that alongside our chemistry and AI platforms allows us to rapidly produce small molecule leads that modulate these stress responses in novel ways," Wilson said in a statement. "What this means is that we can get more selective, structurally unique drug candidates faster by years, significantly increasing the efficiency of drug candidate development."